Cell Harvesting System Market Size & Growth Forecast 2026–2035, By Segments (Application, End-use, Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Cell Harvesting System Market size was more than USD 6.58 Billion in 2025 and is set to grow at a 14.2% CAGR between 2026 and 2035, reaching USD 24.82 Billion by 2035. The industry revenue for 2026 is assessed at USD 7.41 billion.

• Base Year Value (2025): USD 6.58 Billion
• CAGR (2026-2035): 14.2%
• Forecast Year Value (2035): USD 24.82 Billion
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Cell Harvesting System Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America led the market in 2025, supported by a mature biopharmaceutical ecosystem, advanced research institutions, and commercial manufacturing activities requiring reliable, scalable cell harvesting technologies.
  • Asia Pacific is expected to expand at a 15.9% CAGR, driven by biomanufacturing infrastructure expansion, rising regenerative medicine investments, and growing adoption of automated cell harvesting platforms.

• Segment Momentum:

  • Peripheral Blood accounted for 33.28% of the market in 2025 due to its ease of collection, established clinical use, and compatibility with routine therapeutic and diagnostic workflows.
  • R&D Centers are expanding rapidly as growing research in cell therapy and regenerative medicine increases demand for specialized harvesting systems supporting experimental and early-stage therapeutic development.

• Market Expansion Drivers:

  • Rising investment in regenerative medicine and biopharmaceutical R&D accelerating advanced cell harvesting adoption.
  • Increasing prevalence of chronic diseases and demand for stem cell therapies boosting clinical applications.
  • Expansion of automated cryopreservation and bioprocessing technologies improving efficiency and scalability of cell collection systems.

• Leading Market Participants:

  Major companies in the cell harvesting system market include PerkinElmer Inc. (United States), BRAND GMBH + CO KG (Germany), Arthrex, Inc. (United States), Avita Medical, Inc. (Australia), Terumo Corporation (Japan), Teleflex Incorporated (United States), Bertin Technologies (France), Sartorius AG (Germany).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 6.58 Billion
  • Projected Market Size: USD 24.82 Billion by 2035
  • Growth Forecasts: 14.2% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Asia Pacific
  • Core Revenue Segment: Peripheral Blood (Application) | Hospital (End-use) | Automated (Type)
  • Emerging Opportunity Segment: Adipose Tissue (Application) | R & D Centers (End-use) | Automated (Type)

Market Growth Drivers and Industry Trends

Rising investment in regenerative medicine and biopharmaceutical R&D accelerating advanced cell harvesting adoption

As funding flows into cell therapy pipelines, tissue engineering programs, and biologics development, laboratories and manufacturers place greater emphasis on securing viable, high-quality cell populations early in the workflow. This is driving demand for the cell harvesting system market because advanced harvesting platforms help improve yield consistency, reduce contamination risk, and support the tighter process control expected in translational research and GMP-oriented production settings. Investment in regenerative medicine and biopharmaceutical R&D also shifts purchasing behavior toward systems that can integrate with downstream expansion, processing, and analytical steps, supporting market development as organizations move from exploratory research to repeatable, scale-conscious cell manufacturing.

Increasing prevalence of chronic diseases and demand for stem cell therapies boosting clinical applications

The growing burden of chronic and degenerative conditions is increasing the clinical focus on stem cell-based interventions, where the quality and recovery of harvested cells directly affect treatment preparation and therapeutic usability. In the cell harvesting system market, this is reinforcing market demand for platforms capable of handling sensitive cell types with minimal damage while supporting reproducible collection from bone marrow, adipose tissue, peripheral blood, and related sources. As more hospitals, specialty clinics, and cell therapy centers build capabilities around regenerative treatment pathways, procurement increasingly favors harvesting systems that fit clinical workflow requirements, shorten processing time, and support reliable preparation for patient-facing applications.

Expansion of automated cryopreservation and bioprocessing technologies improving efficiency and scalability of cell collection systems

Automation in cryopreservation and bioprocessing is reshaping how cell collection is performed by linking harvesting more closely with standardized storage and manufacturing workflows. This is encouraging market growth in the cell harvesting system market because buyers increasingly prefer systems that reduce manual handling, preserve cell integrity through handoff points, and generate more uniform outputs for downstream freezing, transport, or culture expansion. As cell-based production environments seek scalable operating models, the value of harvesting equipment is judged less as a standalone tool and more as part of an integrated processing chain, increasing market presence for automated and interoperable systems that fit higher-throughput laboratory and production settings.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising investment in regenerative medicine and biopharmaceutical R&D accelerating advanced cell harvesting adoption	2.40%	High	North America, Europe	High	Near Term
Increasing prevalence of chronic diseases and demand for stem cell therapies boosting clinical applications	2.10%	High	North America, Asia Pacific	High	Near Term
Expansion of automated cryopreservation and bioprocessing technologies improving efficiency and scalability of cell collection systems	1.90%	High	Europe, North America, Asia Pacific	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the largest regional share of the cell harvesting system market in 2025, bolstered by its established biopharmaceutical and cell therapy ecosystem, where harvesting technologies are integrated into routine upstream and downstream workflows. The region’s leadership is reinforced by the concentration of advanced research institutions, commercial manufacturing capacity, and clinical development activity that require reliable, scalable cell collection and processing systems. In practice, this creates steady demand for systems that can support reproducibility, contamination control, and higher-throughput production across both research and therapeutic applications.

Asia Pacific is projected to expand at a 15.9% CAGR over the forecast period, with growth in the cell harvesting system market being impelled by the rapid buildout of biomanufacturing infrastructure and rising investment in regenerative medicine and cell-based research. Adoption is accelerating as more regional laboratories, biotech firms, and production facilities move from manual or small-scale processes toward automated and scalable harvesting platforms. This shift is being strengthened by increasing clinical and translational activity, which raises the need for efficient cell recovery solutions that can support larger volumes and more standardized processing.

Key Country Insights

United States

Cell Therapy Manufacturing Hub

The U.S. cell harvesting system market is expanding alongside investments in cell and gene therapy manufacturing infrastructure. Biopharmaceutical companies in the U.S. increasingly seek automated harvesting technologies that improve scalability, process control, and compliance requirements.

Japan

Regenerative Medicine Support

Japan's focus on regenerative medicine and stem cell research is driving demand for precise and efficient cell harvesting technologies. Research institutions and biotechnology companies in Japan increasingly invest in systems that facilitate standardized cell processing workflows.

South Korea

Biomanufacturing Capacity Expansion

South Korea is strengthening its biomanufacturing capabilities, creating demand for cell harvesting systems that support large-scale therapeutic production. Companies in South Korea are adopting automated solutions to improve process efficiency and accelerate clinical development activities.

Germany

Bioprocess Technology Adoption

Germany's strong biopharmaceutical research ecosystem supports demand for advanced cell harvesting systems used in regenerative medicine and biologics production. Laboratories and manufacturers in Germany are prioritizing automated platforms that improve reproducibility and reduce contamination risks.

France

Translational Research Infrastructure

France's cell harvesting system market benefits from ongoing investment in biomedical research centers and advanced therapy programs. Research organizations in France increasingly require systems that enable efficient cell recovery and support complex laboratory workflows.

Italy

Clinical Research Applications

Italy is experiencing steady demand for cell harvesting systems across academic research and regenerative medicine initiatives. Healthcare and research institutions in Italy are focusing on technologies that improve cell viability and streamline sample processing procedures.

Segment Leadership and Growth Trends

  Application Segment Analysis: Peripheral Blood (Largest Segment) vs Adipose Tissue (Fastest-Growing Segment)

Peripheral Blood held a 33.28% share of the cell harvesting system market in 2025, making it the leading application segment. Its leadership is maintained through the practical ease of blood-based cell collection, established clinical familiarity, and broad use across routine therapeutic and diagnostic workflows. Compared with more invasive tissue sources, peripheral blood fits well into standardized harvesting processes and existing hospital and laboratory practices, which helps preserve its strong share in the cell harvesting system market.

Adipose Tissue is emerging as the fastest-growing application in the cell harvesting system market as demand rises for cell sources that support regenerative and advanced therapeutic research. Its growth is being propelled by the increasing relevance of adipose-derived cells in treatment development and experimental medicine, where researchers and clinicians seek accessible tissue sources with expanding application potential. Relative to more conventional sources, adipose tissue is gaining momentum because it is becoming more closely aligned with evolving cell-based therapy requirements and translational research activity.

End-use Segment Analysis: Hospital (Largest Segment) vs R & D Centers (Fastest-Growing Segment)

Hospitals accounted for the largest share of the cell harvesting system market in 2025. Their continued leadership reflects the concentration of patient-facing procedures, established clinical infrastructure, and the need to integrate cell harvesting into treatment settings where collection, processing, and immediate medical oversight can be coordinated efficiently. This operational advantage keeps hospitals at the center of demand for cell harvesting system market solutions, particularly where workflow reliability and clinical handling capacity matter most.

R & D Centers represent the fastest-growing end-use segment in the cell harvesting system market, driven by expanding research activity in cell therapy, regenerative medicine, and related biomedical fields. Growth is accelerating in these settings because research organizations are more actively adopting harvesting systems to support controlled experimentation, protocol development, and early-stage therapeutic exploration. Compared with routine clinical environments, R & D Centers are gaining momentum as innovation efforts intensify and require more specialized cell collection capabilities.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Application	Umbilical Cord, Bone Marrow, Peripheral Blood, Adipose Tissue, Others	Peripheral Blood	Adipose Tissue
End-use	Hospital, Clinic, Academic Institutes, R & D Centers	Hospital	R & D Centers
Type	Manual, Automated	Automated	Automated

Competitive Landscape and Market Positioning

Top players in the cell harvesting system market:

1. PerkinElmer Inc. (United States)

2. BRAND GMBH + CO KG (Germany)

3. Arthrex Inc. (United States)

4. Avita Medical Inc. (Australia)

5. Terumo Corporation (Japan)

6. Teleflex Incorporated (United States)

7. Bertin Technologies (France)

8. Sartorius AG (Germany)

The cell harvesting system market is evolving through advancements in bioprocessing efficiency and cell recovery precision. New system designs are being introduced to improve yield and process control. Research efforts are enhancing scalability and contamination reduction techniques. Collaborative innovation is also supporting progress in biopharmaceutical manufacturing workflows.

Industry Development/News

Company Name	Date	Key Development
AstraZeneca	Mar-25	AstraZeneca acquired EsoBiotec for USD 425 million to strengthen its in vivo cell therapy portfolio. The acquisition expands the company's capabilities across advanced cell therapy development, supporting broader commercialization within the cell harvesting and processing ecosystem.
Thermo Fisher Scientific	Feb-25	Thermo Fisher announced the USD 4.1 billion acquisition of Solventum's purification and filtration business. The transaction expands complementary bioproduction capabilities, strengthening manufacturing infrastructure supporting advanced cell therapy and biologics production.
Terumo Blood and Cell Technologies	Jan-25	Terumo Blood and Cell Technologies partnered with FUJIFILM Irvine Scientific to combine the Quantum Flex platform with PRIME-XV media for rapid T-cell expansion. The collaboration enhances integrated workflows supporting scalable cell manufacturing and harvesting applications.
Sumitomo Chemical	Dec-24	Sumitomo Chemical established RACTHERA to expand its regenerative medicine business, targeting approximately ¥350 billion in revenue by the late 2030s. The initiative represents a strategic investment in advanced cell therapy manufacturing and commercialization capabilities.
Terumo Blood and Cell Technologies	Mar-24	Terumo Blood and Cell Technologies partnered with the CiRA Foundation to accelerate industrial adoption of induced pluripotent stem cell technologies. The collaboration supports development and commercialization of regenerative therapies by strengthening cell processing and manufacturing capabilities.